Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease.

Autoantibodies against oxidized low density lipoprotein (oxLDL) have been proposed to be independent predictors of atherosclerotic vascular disease. Because the levels of autoantibodies against oxLDL and cardiolipin might be modified by the presentation and severity of coronary heart disease (CHD), we measured their levels in patients with different manifestations of CHD (n=415, mean age 61 years, range 33 to 74 years) in a subset of the European Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) study. There were 109 patients with coronary artery bypass surgery, 106 patients with balloon angioplasty, 101 patients with acute myocardial infarction, and 99 patients with acute myocardial ischemia. Autoantibodies were measured by ELISA. Food records and fatty acid profiles of serum cholesteryl esters were used to evaluate dietary intake. Anti-oxLDL antibodies were significantly higher in the group with acute myocardial infarction than in other groups in men (coronary artery bypass surgery 1.91+/-1. 41, balloon angioplasty 2.11+/-2.19, acute myocardial infarction 2. 52+/-2.05, and acute myocardial ischemia 1.96+/-1.78; P=0.022, mean+/-SD) but not in women. The titers of anti-cardiolipin antibodies did not differ among the patient groups. Neither of the autoantibodies was associated with recurrent coronary events. Anti-oxLDL and anti-cardiolipin autoantibodies were not correlated with serum total cholesterol, high density lipoprotein cholesterol, or triglycerides, except that in women anti-oxLDL antibodies and triglycerides were positively correlated (r=0.225, P=0.011). In men, anti-cardiolipin antibodies were higher in the lowest quartiles of dietary intakes of vitamin E and polyunsaturated fat. Dietary intakes of vitamin E and polyunsaturated fat were correlated (r=0. 588, P<0.001). In conclusion, autoantibodies against oxLDL were associated with myocardial infarction in men. Anti-cardiolipin autoantibodies were inversely correlated with dietary intakes of vitamin E and polyunsaturated fat in men with CHD.

[1]  H. Drexler,et al.  Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. , 1999, Journal of the American College of Cardiology.

[2]  S. Ylä-Herttuala,et al.  Is oxidized low-density lipoprotein present in vivo? , 1998, Current opinion in lipidology.

[3]  O. Wiklund,et al.  Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Steinberg.  Oxidative Modification of LDL and Atherogenesis , 1998 .

[5]  L. Berglund,et al.  Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  T. Lehtimäki,et al.  In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. , 1997, Journal of the American College of Cardiology.

[7]  E. Erdmann,et al.  Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Folsom,et al.  Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study. The ARIC Study Investigators. Atherosclerosis Risk in Communities. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[9]  D. Steinberg,et al.  Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. , 1997, Circulation.

[10]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[11]  G. Bellomo,et al.  Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. , 1997, European heart journal.

[13]  A. Shiran,et al.  Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. , 1996, The American journal of medicine.

[14]  O. Vaarala.  Antiphospholipid Antibodies and Atherosclerosis , 1996, Lupus.

[15]  L. Niskanen,et al.  Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R. Roubey.  Immunology of the antiphospholipid antibody syndrome. , 1996, Arthritis and rheumatism.

[17]  R. Terkeltaub,et al.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. , 1996, The Journal of clinical investigation.

[18]  J. Boer,et al.  Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. , 1996, Atherosclerosis.

[19]  P. Reaven,et al.  Oxidized low density lipoproteins in atherogenesis: role of dietary modification. , 1996, Annual review of nutrition.

[20]  G. Palomaki,et al.  Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipoprotein- and oxidation-related analytes. , 1995, Journal of autoimmunity.

[21]  T. Nikkari,et al.  Fatty acid composition of serum lipid fractions in relation to gender and quality of dietary fat. , 1995, Annals of medicine.

[22]  U. de Faire,et al.  Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[23]  LeenaTenkanen,et al.  Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men , 1995 .

[24]  L. Tenkanen,et al.  Antibody against oxidized low-density lipoprotein predicting myocardial infarction. , 1994, Archives of internal medicine.

[25]  G. Hughes,et al.  beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. , 1994, Arthritis and rheumatism.

[26]  G. Bellomo,et al.  LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  P. Pietinen,et al.  The 1992 Dietary Survey of Finnish Adults , 1994 .

[28]  W. Klein,et al.  Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. , 1994, Cardiology.

[29]  K. Phadke,et al.  Anticardiolipin antibodies in ischaemic heart disease: marker or myth? , 1993, British heart journal.

[30]  M. Jauhiainen,et al.  Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus , 1993, The Lancet.

[31]  M. Stampfer,et al.  Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis , 1992, Annals of Internal Medicine.

[32]  I. Penttilä,et al.  Rapid separation of serum lipids for fatty acid analysis by a single aminopropyl column. , 1992, Journal of lipid research.

[33]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[34]  H. Arnesen,et al.  Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke , 1992, The Lancet.

[35]  V. Piironen,et al.  The tocopherol, tocotrienol, and vitamin E content of the average Finnish diet. , 1991, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[36]  T. Barbui,et al.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.

[37]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. de Caterina,et al.  Prevalence of anticardiolipin antibodies in coronary artery disease. , 1990, The American journal of cardiology.

[39]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[40]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Strauss,et al.  Anti-cardiolipin antibodies in ischaemic heart disease. , 1988, Clinical and experimental immunology.

[42]  G. Daggard,et al.  CORONARY ARTERY BYPASS GRAFT FAILURE—AN AUTOIMMUNE PHENOMENON? , 1986, The Lancet.

[43]  A. Hamsten,et al.  ANTIBODIES TO CARDIOLIPIN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION: AN ASSOCIATION WITH RECURRENT CARDIOVASCULAR EVENTS , 1986, The Lancet.